University of Mississippi

eGrove
Eastland Correspondence: Kennedy
Administration

James O. Eastland Executive Branch
Correspondence

4-10-1962

President John F. Kennedy to Senator James O. Eastland, 10 April
1962
John F. Kennedy

Follow this and additional works at: https://egrove.olemiss.edu/joecorr_d
Part of the American Politics Commons

Recommended Citation
Kennedy, John F., "President John F. Kennedy to Senator James O. Eastland, 10 April 1962" (1962).
Eastland Correspondence: Kennedy Administration. 11.
https://egrove.olemiss.edu/joecorr_d/11

This Book is brought to you for free and open access by the James O. Eastland Executive Branch Correspondence
at eGrove. It has been accepted for inclusion in Eastland Correspondence: Kennedy Administration by an
authorized administrator of eGrove. For more information, please contact egrove@olemiss.edu.

,
THE WHITE HOUSE
WASHINGTON

April 10, 1962

Dear Senator:
In the me s sage I sent to the Congre s s on March 14, I calle d attention to
the need for new legislative authority to advance and protect the interests
of consumers in the marketing of drugs.

S. 1552, which is now pending before your Committee, incorporates the
major recommendations I made. It will strengthen and broaden existing
laws in the food and drug field, contribute toward better, safer and less
expensive medicine s, and establish a better system of enforcement. As
you know, the bill is the outgrowth of twenty-eight months of intensive
investigation and hearings by your Subcommittee on Antitrust and Monopoly.
I believe that early passage of this legislation will substantially improve
the ability of the drug industry to serve the Nation and help provide consumers with quality drugs at low competitive prices.
I understand that the members of the Subcommittee on Patents have decided that the compulsory licensing feature of the legislation require s
further study and consideration. I would hope that this would not, hO'Wever,
delay enactment of the other provisions of the bill -- provisions which will
establish neces sary safe guards to as sure the reliability and effecti vene ss
of drugs placed on the market, provide for standardization of drug names,
and thereby encourage physicians to pre scribe drugs by nonproprietary
rather than by brand name s, require disclosure of adverse as well as
beneficial effects of drugs in drug promotion, and assure consideration
of therapeutic effectiveness in the granting of patents for drugs that are
modifications of other drugs.
The me ssage I sent to the Congre ss made several other sugge stions which,
it would seem to me, might appropriately be included in the bill now before
your Committee. They are:
1. Drug manufacturers should be required to keep records on
and report to the Department of Health, Education and Welfare
any indications of adverse effects from the use of a new drug
or antibiotic.
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2. The Department of Health, Education and Welfare should
be empowered to withdraw approval of a new drug on the basis
of a substantial doubt of its efficacy or safety.

3. The provisions requiring drug manufacturers to maintain
facilities and controls to assure the reliability of their product,
and to institute more effective inspection to determine whethe r
drugs are being manufactured in accordance with the law, cannot
feasibly be limited to a particular clas s of drugs and should
therefore be made applicable to over-the-counter as well as
prescription drugs.

4. An enforceable system of preventing the illicit distribution
of habit-forming barbiturates and amphetamines should be
provided.
The need for the se amendmends is based upon the accumulated years of
experience of the Food and Drug Administration, and they appear to be
properly within the scope of the subject matter dealt with in the extensive
hearings of the Subcommittee on Antitrust and Monopoly.
In addition, I recommend two minor procedural change s:

1. In the section having to do with the rendering of advisory
opinions by the Department of Health, Education and Welfare
to the Patent Office on the therapeutic effect of modifications
and combinations, I sugge st that the requirement providing the
applicant with an opportunity for a plenary hearing be deleted.
Under the provisions of S.1552 in its earlier form, the Secretary's
finding was conclusive and therefore should have required a formal
hearing. But since the bill in its pre sent form require s no binding decision to be made by the Secretary, the requirement of the
hearing seems inappropriate and would tend to unduly delay the
rendition of the Secretary1s purely advisory opinion to the Commissioner. The action of the Commissioner is, of course,
subject to well established de novo judicial review.
2. The provision requiring the filing of patent agreements with
the Commissioner of Patents should more properly be in the
form of an amendment to the Patent Act rather than the Sherman
Act.
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I have asked the Department of Health, Education and Welfare to transmit to you promptly any additional recommendations to strengthen,
clarify, or improve the bill that it may have and that will not require
additional hearings or substantially delay action on the bill.
It would not appear that the consideration of the se proposed change s
should occasion any further delay in the approval of this important measure.
With the above changes, S. 1552 adequately deals with the most pressing
problems in the drug field, and it is my sincere wish that it be enacted
during the current session of the Congress. Your cooperation and assistance to this end will be greatly appreciated.

Sincerely

Honorable James O. Eastland
United State s Senate
Washington, D. C.

